Free Trial

Nantahala Capital Management LLC Raises Stake in COMPASS Pathways plc (NASDAQ:CMPS)

COMPASS Pathways logo with Medical background

Nantahala Capital Management LLC lifted its stake in shares of COMPASS Pathways plc (NASDAQ:CMPS - Free Report) by 400.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,000,000 shares of the company's stock after acquiring an additional 800,000 shares during the period. Nantahala Capital Management LLC owned 1.46% of COMPASS Pathways worth $3,780,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. purchased a new position in shares of COMPASS Pathways in the fourth quarter valued at approximately $41,000. Wealthfront Advisers LLC purchased a new position in COMPASS Pathways in the 4th quarter valued at approximately $43,000. Flagship Harbor Advisors LLC acquired a new position in shares of COMPASS Pathways in the fourth quarter worth $43,000. Conservest Capital Advisors Inc. increased its position in shares of COMPASS Pathways by 28.9% during the fourth quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company's stock worth $51,000 after acquiring an additional 3,000 shares during the period. Finally, Simplify Asset Management Inc. acquired a new stake in shares of COMPASS Pathways in the fourth quarter valued at $54,000. 46.19% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on CMPS. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of COMPASS Pathways in a research report on Friday, March 28th. Royal Bank of Canada reiterated an "outperform" rating and issued a $18.00 price target on shares of COMPASS Pathways in a research note on Wednesday, January 15th. HC Wainwright restated a "buy" rating and issued a $45.00 price objective on shares of COMPASS Pathways in a report on Tuesday, March 4th. Canaccord Genuity Group lowered their target price on shares of COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, February 28th. Finally, Stifel Nicolaus initiated coverage on COMPASS Pathways in a research note on Thursday, February 27th. They issued a "buy" rating and a $11.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, COMPASS Pathways has a consensus rating of "Buy" and an average target price of $20.20.

Get Our Latest Stock Analysis on CMPS

COMPASS Pathways Stock Up 2.2 %

Shares of NASDAQ CMPS traded up $0.09 during mid-day trading on Friday, reaching $4.19. The company had a trading volume of 630,372 shares, compared to its average volume of 797,755. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. The firm has a 50 day simple moving average of $3.34 and a two-hundred day simple moving average of $4.13. The stock has a market cap of $388.30 million, a P/E ratio of -1.90 and a beta of 2.34. COMPASS Pathways plc has a 52-week low of $2.49 and a 52-week high of $9.63.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01). Sell-side analysts predict that COMPASS Pathways plc will post -2.33 earnings per share for the current year.

COMPASS Pathways Profile

(Free Report)

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

Further Reading

Institutional Ownership by Quarter for COMPASS Pathways (NASDAQ:CMPS)

Should You Invest $1,000 in COMPASS Pathways Right Now?

Before you consider COMPASS Pathways, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and COMPASS Pathways wasn't on the list.

While COMPASS Pathways currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines